Our portfolio
Impacting the patient journey: From diagnosis to surgical intervention to therapy
A new era of cancer care
Radiation has long been a cornerstone of cancer care, but its impact in metastatic disease has been limited, and higher doses can lead to significant side effects. Today, the shift from external beam radiation to systemically delivered, targeted radiation is transforming how cancer is diagnosed, staged, and treated.
We are developing targeted radiopharmaceutical therapies that can be used alone or in combination, each linked to a companion imaging agent. This theranostic approach enables precise detection, targeted treatment, and real-time monitoring — advancing truly personalized cancer care.
Illuccix® for prostate cancer imaging
Illuccix® (kit for the preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection, also known as ⁶⁸Ga-PSMA-11 injection) has been approved in United States, Canada, Australia, United Kingdom, Brazil and countries in the European Union.
Registrations vary country to country, always check the approved local product label. Full Product information available below.
Gozellix® for prostate cancer imaging
Gozellix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) has been approved by the United States Food and Drug Administration (FDA).
Registrations vary country to country, always check the approved local product label. Full Product information available below.
